TEST:

ThyroidPrint©

These guidelines emphasize the need for standardized protocols and equitable access to such testing. Molecular diagnostics should be embraced as complementary tools within multidisciplinary care to optimize patient outcomes while reducing unnecessary interventions in thyroid nodule management.

In this series, NIFTP showed indolent behaviour and excellent prognosis. Ultrasonographically, 90% presented as ACR-TIRADS 3 or 4, with less than 10% as ACR-TIRADS 5. Regarding FNAB, nearly half were indeterminate, one-third were Bethesda V, and none Bethesda VI. No significant differences in clinical outcomes were found between lobectomy and TT.

This is our first description about the use of ThyroidPrint® test in our hospital. This is a very easy technique to perform and helps for a clinical decision about the thyroidectomy in AUS/FN thyroid nodules.

This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.

False-positive cases included four benign follicular nodules, six follicular and four oncotytic adenomas. Our results show that, physicians chose active surveillance instead diagnostic surgery in all patients with a benign ThyroidPrint® result, reducing the need for diagnostic surgery in 67% in patients with preoperative diagnosis of ITN.

No abstracts available

Corporate presentation